NCT07515599Recruiting
Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension
A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy of OLMETEC Tab. (or OLMETEC Plus Tab.) on Nocturnal Blood Pressure Control in Korean Patients With Stage Ⅰ Hypertension
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 12000 (estimated)
- First submitted
- 31 Mar 2026
- Start date
- 17 Sept 2025
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Diseases
- High blood pressure
- NCT number
- NCT07515599
What you commit to
- Study type: Observational
- Planned participants: 12000
- From 17 Sept 2025 to the primary completion date, 31 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with secondary hypertension
- Patients with severe hypertension requiring immediate pharmacological i-ntervention
- Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs
- Patients with severe renal impairment or severe hepatic impairment
Other
- Patients who are pregnant, planning to become pregnant, or breastfeeding
- Patients who are unable to comply with study procedures, including ABPM
- Patients who are deemed inappropriate for participation by the investigator
Who the study is looking for
- Adults aged ≥19 years
- Patients diagnosed with stage 1 hypertension according to clinical guidelines
- Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice
- Patients who are able to undergo ambulatory blood pressure monitoring (ABPM)
- Patients who voluntarily agree to participate and provide written informed consent
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Multiple centers in Republic of Korea Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.